Compare AMTB & GLUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTB | GLUE |
|---|---|---|
| Founded | 1979 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.2B |
| IPO Year | 2018 | 2021 |
| Metric | AMTB | GLUE |
|---|---|---|
| Price | $29.19 | $11.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $31.88 | $28.50 |
| AVG Volume (30 Days) | 282.6K | ★ 949.3K |
| Earning Date | 10-22-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.26% | N/A |
| EPS Growth | ★ 386.36 | N/A |
| EPS | ★ 0.97 | N/A |
| Revenue | N/A | ★ $123,672,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.20 | N/A |
| P/E Ratio | ★ $30.06 | $72.42 |
| Revenue Growth | N/A | ★ 63.54 |
| 52 Week Low | $15.62 | $7.24 |
| 52 Week High | $30.60 | $25.77 |
| Indicator | AMTB | GLUE |
|---|---|---|
| Relative Strength Index (RSI) | 47.22 | 28.92 |
| Support Level | $28.31 | N/A |
| Resistance Level | $30.19 | $15.00 |
| Average True Range (ATR) | 0.78 | 0.59 |
| MACD | -0.11 | 0.05 |
| Stochastic Oscillator | 25.67 | 9.06 |
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programs in clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).